Quantitative phosphoproteomics uncovers synergy between DNA-PK and FLT3 inhibitors in acute myeloid leukaemia

Heather C Murray; Anoop K Enjeti; Richard G S Kahl; Hayley M Flanagan; Jonathan Sillar; David A Skerrett-Byrne; Juhura G Al Mazi; Gough G Au; Charles E de Bock; Kathryn Evans; Nathan D Smith; Amanda Anderson; Brett Nixon; Richard B Lock; Martin R Larsen; Nicole M Verrills; Matthew D Dun

doi:10.1038/s41375-020-01050-y

Quantitative phosphoproteomics uncovers synergy between DNA-PK and FLT3 inhibitors in acute myeloid leukaemia

Leukemia. 2021 Jun;35(6):1782-1787. doi: 10.1038/s41375-020-01050-y. Epub 2020 Oct 16.

Authors

Heather C Murray¹, Anoop K Enjeti^{2

3

4}, Richard G S Kahl¹, Hayley M Flanagan¹, Jonathan Sillar^{1

2}, David A Skerrett-Byrne^{5

6}, Juhura G Al Mazi¹, Gough G Au⁵, Charles E de Bock⁷, Kathryn Evans⁷, Nathan D Smith⁸, Amanda Anderson⁶, Brett Nixon⁶, Richard B Lock⁷, Martin R Larsen⁹, Nicole M Verrills^#¹⁰, Matthew D Dun^#¹¹

Affiliations

¹ Cancer Research Program, Hunter Medical Research Institute, School of Biomedical Sciences and Pharmacy Faculty of Health and Medicine, University of Newcastle, Callaghan, NSW, 2308, Australia.
² Calvary Mater Newcastle Hospital, Waratah, NSW, 2298, Australia.
³ NSW Health Pathology, John Hunter Hospital, Lookout Road, New Lambton Heights, NSW, Australia.
⁴ School of Medicine and Public Health Faculty of Health and Medicine, University of Newcastle, Callaghan, NSW, 2308, Australia.
⁵ Viruses, Infections/Immunity, Vaccines and Asthma Program, Hunter Medical Research Institute, and School of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, University of Newcastle, Callaghan, NSW, 2308, Australia.
⁶ Priority Research Centre for Reproductive Science, School of Environmental and Life Sciences, University of Newcastle, Callaghan, NSW, 2308, Australia.
⁷ Children's Cancer Institute Australia, School of Women's and Children's Health, University of New South Wales, Sydney, NSW, Australia.
⁸ Analytical and Biomolecular Research Facility, Advanced Mass Spectrometry Unit, University of Newcastle, Callaghan, NSW, 2308, Australia.
⁹ Department of Molecular Biology and Biochemistry, Protein Research Group, University of Southern Denmark, Odense, 5230, Denmark.
¹⁰ Cancer Research Program, Hunter Medical Research Institute, School of Biomedical Sciences and Pharmacy Faculty of Health and Medicine, University of Newcastle, Callaghan, NSW, 2308, Australia. nikki.verrills@newcastle.edu.au.
¹¹ Cancer Research Program, Hunter Medical Research Institute, School of Biomedical Sciences and Pharmacy Faculty of Health and Medicine, University of Newcastle, Callaghan, NSW, 2308, Australia. matt.dun@newcastle.edu.au.

^# Contributed equally.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Benzothiazoles / pharmacology*
Chromones / pharmacology*
DNA-Activated Protein Kinase / antagonists & inhibitors*
Drug Synergism*
Drug Therapy, Combination
Humans
Leukemia, Myeloid, Acute / drug therapy*
Leukemia, Myeloid, Acute / metabolism
Leukemia, Myeloid, Acute / pathology
Morpholines / pharmacology*
Phenylurea Compounds / pharmacology*
Phosphoproteins / metabolism*
Proteome / drug effects*
Tumor Cells, Cultured
fms-Like Tyrosine Kinase 3 / antagonists & inhibitors*

Substances

8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one
Benzothiazoles
Chromones
Morpholines
Phenylurea Compounds
Phosphoproteins
Proteome
quizartinib
FLT3 protein, human
fms-Like Tyrosine Kinase 3
DNA-Activated Protein Kinase